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Background and purpose: Poor quality radiotherapy can detrimentally affect outcomes in clinical trials. Our
purpose was to explore the potential of knowledge-based planning (KBP) for quality assurance (QA) in clinical
trials.
Materials and methods: Using 30 in-house post-prostatectomy radiation treatment (PPRT) plans, an iterative KBP
model was created according to the multicentre clinical trial protocol, delivering 64 Gy in 32 fractions. KBP was
used to replan 137 plans. The KB (knowledge based) plans were evaluated for their ability to fulfil the trial
constraints and were compared against their corresponding original treatment plans (OTP). A second analysis
between only the 72 inversely planned OTPs (IP-OTPs) and their corresponding KB plans was performed.
Results: All dose constraints were met in 100% of KB plans versus 69% of OTPs. KB plans demonstrated signif
icantly less variation in PTV coverage (Mean dose range: KB plans 64.1 Gy-65.1 Gy vs OTP 63.1 Gy-67.3 Gy, p <
0.01). KBP resulted in significantly lower doses to OARs. Rectal V60Gy and V40Gy were 17.7% vs 27.7% (p <
0.01) and 40.5% vs 53.9% (p < 0.01) for KB plans and OTP respectively. Left femoral head (FH) V45Gy and
V35Gy were 0.4% vs 7.4% (p < 0.01) and 7.9% vs 34.9% (p < 0.01) respectively. In the second analysis plan
improvements were maintained.
Conclusions: KBP created high quality PPRT plans using the data from a multicentre clinical trial in a single
optimisation. It is a powerful tool for utilisation in clinical trials for patient specific QA, to reduce dose to sur
rounding OARs and variations in plan quality which could impact on clinical trial outcomes.
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1. Introduction

2.2. Original TROG 08.03 plan QA

During clinical trials, poor quality radiation therapy (RT) may
detrimentally affect the anticipated benefits of an intervention,
impacting on clinical trial results [1–3]. Deviations in tumour volume
delineation and inadequate planning can compromise local control and
overall survival [1]. A second analysis of the RTOG 0126 prostate cancer
trial identified a substantial number of patients at risk of rectal toxicity
due to suboptimal plans [4]. A critical component of multicentre trials in
radiation oncology is quality assurance (QA) to ensure that participating
institutions are delivering consistent doses to the target volumes (TV)
and adequately sparing organs at risk (OARs). Deviations from trial
protocols have been documented to reduce efficacy and increase normal
tissue complication rates [2,3,5]. However, the QA process can be
resource intensive, yet generic and passing trial QA does not necessarily
indicate that the plan is the optimal plan for the patient.
Automated planning is a tool which aims to achieve plan consistency
and improved plan quality as well as to increase efficiency in a RT
department [6]. It has a further role in performing patient specific QA of
treatment plans [7–10]. A Knowledge-based planning (KBP) model is
trained using a library of high quality plans. By correlating geometric
features of the plans included in the model with the OAR doses achieved,
the model is able to rapidly produce estimated dose volume histogram
(DVH) curves for the individual patient based on the OARs and PTVs of a
delineated CT scan [11,12]. Treatment plans are created using optimi
sation objectives obtained from the predicted DVHs. The OAR doses
achieved in the KB plans strongly correlate with the OAR doses pre
dicted by the model [7,12].
There have been an increasing number of publications reviewing the
role of KBP to improve the plan consistency, the efficiency of planning
and for treatment plan QA [9,13–21]. The TROG 08.03 clinical trial
dataset provided an opportunity where plans, created in multiple
treatment centres and having undergone centralised QA could be
replanned using a KBP model and compared to the original treatment
plan (OTP). Our hypothesis was that KBP would produce plans, with less
variation in target coverage and similar or improved OAR doses than the
original treatment plans in a single optimisation. The purpose of this
study was to explore the potential of KBP as a powerful and efficient tool
in clinical trials for QA and planning purposes.

Patients included in the trial were treated by 46 clinicians at 32
different hospitals [26]. All clinicians and sites had to submit a cre
dentialing dummy run prior to recruitment as part of QA. For every
patient, TV and the treatment plans were reviewed by an independent
QA radiation oncologist before the start of treatment. Any prospectively
identified major protocol violations or a sum of minor violations
required correction and resubmission [26]. During real time review,
data, including doses to targets and OARs as well as violations, were
stored on the trial evaluation form. If a resubmission was required, QA
was again performed and a second trial evaluation form was completed.
The OTP cohort consisted of 65 patients planned with 3DCRT, and 72
that had been inversely planned, 67 with IMRT and 5 with volumetric
modulated arc therapy (VMAT). In the IMRT plans, the median number
of fields was 7, and the range was 5 to 9.

2. Materials and methods

2.4. Replanning using the TROG 08.03 KBP model

Trans-Tasman Radiation Oncology Group (TROG) 08.03 RAVES
study is a recently completed multicentre clinical trial comparing the
role of adjuvant or early salvage post-prostatectomy radiation therapy
(PPRT) [22,23] This secondary analysis performed using the TROG
08.03 trial dataset was approved by the TROG cancer research scientific
committee and ethics. OTPs and subsequent plans created with KBP
were compared against the trial protocol for compliance in target
coverage, OAR doses and violations.

PPRT was delivered to 238 of the 333 patients enrolled on the trial
[23]. After central de-identification, 169 patient datasets comprising
planning CT scans with original contours and 160 trial evaluation forms
were received from TROG. The final cohort of 137 patients comprised
only those patients with both a CT dataset and a trial evaluation form.
Using the KBP model, with no manual intervention, a new plan was
created for each of the patients in the cohort. The plans were created
using a 7-field IMRT technique and 6MV photons. All plans were nor
malised according to the original trial protocol. Only a single optimi
sation was allowed. The treatment planning time was defined as the
total time measured from the start of the optimisation to the end of
calculation of the treatment plan.

2.3. KBP model creation
RapidPlan (RP) (Varian Medical Systems, Palo, Alto, CA) is a KBP
tool which was used for this study [6]. RapidPlan software version 15.6
was used to create the model. The TROG 08.03 PPRT KBP model was an
‘iterative’ model, created using 30 in house PPRT plans from the
Northern Sydney Cancer Centre database that had been contoured ac
cording to the PPRT consensus guidelines [24,27]. Thirty 7-field IMRT
PPRT plans using 6MV energy were generated by the department expert
prostate planners and repeatedly optimised to achieve the clinical ob
jectives detailed in the trial protocol. All plans were reviewed by radi
ation oncologists. These 30 plans were then included in the development
of the iterative IMRT PPRT KBP model. The model was re-trained
initially using outputted PPRT IMRT plans as input for the next itera
tion of the model [27,28]. Included plans were checked for outliers and
none were found. A combination of point values, lines, generated and
fixed were used, as demonstrated in Supplementary table 2. No trial
patients were included in the development of the KBP model. The model
was adapted to achieve TROG 08.03 target dose coverage but with the
goal of delivering the lowest possible doses to the OARs. Prior to use, the
model was validated using 20 independent patients, ensuring that the
plans produced met the trial protocol dose constraints.

2.1. TROG 08.03 trial protocol
All patients were contoured according to PPRT consensus guidelines
as specified by the trial protocol [24]. The prescribed dose was 64 Gy in
32 fractions to the prostate bed. The trial specified centres had to meet
minimum TPS requirements. For patients planned with 3D conformal
radiation therapy (3DCRT), the dose was prescribed to the ICRU 50
reference point, at the centre of the PTV [25]. For patients planned using
an Intensity Modulated Radiation Therapy (IMRT) technique, the dose
was prescribed to a volume so that 98% of the PTV received at least 95%
of the prescribed dose. The trial protocol only specified constraints for
the PTV, rectum and left femur. There were no constraints for Bladder
and right femoral head. Table of dose constraints is available in Sup
plementary Table 1.

2.5. Evaluation of KBP model performance
In this report, plans created using the KBP model are denoted
knowledge-based plans (KB plans) and the original treatment plans on
which patients were treated in the trial are denoted OTPs. The KB plans
were evaluated for their ability to meet the trial protocol objectives and
were compared against the OTPs with respect to the target dose
coverage and OAR sparing according to the trial dosimetric parameters
(Supplementary Table 1). Protocol violations were recorded and
compared with OTP violations. The initial analysis included all 137
patients in the cohort, irrespective of the treatment technique (3DCRT or
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IMRT/VMAT) used. A second analysis was performed between the 72
inversely-planned OTPs (IP-OTPs) and their corresponding KB plans (IPKBPs).

3.2. Comparison of full OTP cohort with KB plans
Mean doses and standard deviations for dosimetric parameters ac
cording to the protocol are represented in Table 2. There was signifi
cantly less variation in PTV coverage in the KB plans (p < 0.01). This is
visually demonstrated in Fig. 1. KBP resulted in significantly lower doses
to OARs. Rectal V60Gy and V40Gy were 17.7% vs 27.7% (p < 0.01) and
40.5% vs 53.9% (p < 0.01) for KB plans and OTP respectively (Fig. 2).
Mean rectal dose was also significantly lower (38.3 Gy vs 42.4 Gy, p <
0.01). Of note, the rectal max dose was significantly higher in the KB
plans (66.5 Gy vs 64.5 Gy, p < 0.01). In dosimetric parameters to the left
femoral head, KBP resulted in significantly lower doses as well as
significantly reduced variation in dose (Fig. 3). Of note is the reduction
in the range of FH volume receiving 35 Gy, from 0 to 91% in OTP plans
down to 0–20% in KB plans.

2.6. Statistical analysis
Statistical analysis was performed to compare the different dosi
metric parameters of OTP and KB plans. Welch’s t-tests was used to
compare means of the 17 parameters between OTP and KB plans. F-tests
were used to compare the variances of the two planning approaches. All
analyses were repeated for the IP-OTP. No adjustments have been made
for multiplicity. All statistical analysis was performed with R version
3.6.3.
2.7. Review of dose constraints

3.3. Secondary comparison of the IP-OTP cohort and their corresponding
KB plans (IP-KBP)

Based on the doses to OARs in the KB plans, achievable dose con
straints were created. Suggested dose constraints were based on the 90th
percentile and the minor violations on the 99th percentile, with major
violations being outside of the 99th percentile.

As demonstrated in table 2, plan improvements were maintained in
the IP-KBP group, with significantly less variation in PTV target
coverage (p < 0.01) and lower doses to OARs. Rectal V60Gy, V40Gy and
mean dose were significantly lower (p < 0.01), although again the rectal
max dose was significantly higher in the IP-KB plans (66.8 Gy vs 64.8
Gy) (Fig. 2). The volume percent of the FH receiving each dose was
similar between the IP-OTP and IP-KBP, however doses in the KB plans
were more consistent with less dosimetric outliers (Fig. 3).

3. Results
Each KB plan took less than 5 minutes to complete.
3.1. Violations and resubmissions

3.4. Achievable dose constraints

As demonstrated in Table 1, approximately 70% of OTPs met all dose
constraints, with 42 plans having either a minor or major violation or
both. There were 7 major and 54 minor violations recorded. The most
frequent minor violations occurred in the PTV median and mean dose
and rectal V40Gy (%). Resubmission due to violations was required in
approximately 20% of the cases, with resubmission occurring more
frequently in the 3DCRT groups (approximately 32%). The number of
recorded violations and resubmissions did not necessarily correspond as
some plans requiring resubmission had multiple violations and other
plans with only minor violations did not require resubmission. In the KB
plans, all dose constraints were met in 100% of plans, with no major or
minor violations recorded (Table 1).

As demonstrated in Table 3, the volume of rectum receiving 60 Gy
was <25% in 90% of KB plans and <32% in 99% of KB plans. The
volume of rectum receiving 40 Gy was <51% in 90% and <57% in 99%
of KB plans. The volumes of left femur that received 35 Gy was <15%
and 20% in 90% and 99% of KB plans respectively.
4. Discussion
The TROG 08.03 clinical trial data was used to investigate the role of
KBP in QA and planning for clinical trials to determine if the quality of

Table 1
Table of minor and major violations according to TROG 08.03 protocol, recorded for the full cohort OTP (orange), the OTP separated according to planning (3DCRT vs
inverse planning) (green) and the KB plans (blue). Number of resubmissions are also reported. (Abbreviations: OTP: Original treatment plan, 3D CRT: 3D conformal
radiation therapy, KB: Knowledge-based).
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Table 2
Comparison of mean and standard deviations of trial dosimetric parameters between all the 137 OTPs and their corresponding KBPs. The table also includes the
secondary comparison of the mean and standard deviations of the 72 IP-OTPs and their corresponding IP-KBPs. (Abbreviations: OTP: Original treatment plan, KBP:
Knowledge-based plan, IP-OTP: Inversely planned Original treatment plan, IP-KBP: Inversely planned Knowledge-based plan).
Structure

Parameter

OTP
Mean (
±SD)
N ¼ 137

KBP
Mean (
±SD)
N ¼ 137

P value
(comparing
means)

P value
(comparing
variances)

IP-OTP
Mean (
±SD)
N ¼ 72

IP-KBP
Mean (
±SD)
N ¼ 72

PTV

Mean dose (Gy)

64.5
(±0.7)
64.7
(±0.8)
66.4
(±1)
61.3
(±2)
99.2
(±2)
64.8
(±2.4)
66.4
(±1)
63.8
(±1.3)
27.7
(±6.9)
53.9
(±7.9)
42.4
(±4.3)
64.5
(±3.6)
34.9
(±31)
7.4
(±12)
0.1
(±0.9)
28.4
(±7.3)
44.1
(±7.5)

64.5
(±0.2)
64.7
(±0.3)
67.4
(±0.3)
60.8
(±0.1)
98.1
(±0.1)
65.5
(±0.2)
67.4
(±0.3)
64.1
(±0.1)
17.7
(±5.6)
40.5
(±7.7)
38.3
(±3.9)
66.5
(±0.9)
7.9
(±4.8)
0.4
(±0.8)
0.0

0.66

<0.01

0.8

<0.01

<0.01

<0.01

0.01

<0.01

<0.01

<0.01

0

<0.01

<0.01

<0.01

<0.01

<0.01

<0.01

0.01

<0.01

0.74

<0.01

0.27

<0.01

<0.01

<0.01

<0.01

64.5
(±0.2)
64.7
(±0.2)
67.4
(±0.3)
60.8
(±0.1)
98.1
(±0.1)
65.5
(±0.2)
67.5
(±0.3)
64.1
(±0.1)
19.6
(±5.5)
42.8
(±8.2)
39
(±4.3)
66.8
(±0.8)
8.8 (±5)

<0.01

<0.01

0.30

<0.01

64.7
(±0.8)
64.9
(±0.9)
66.8
(±1)
61.4
(±1)
98.6
(±1)
65.4
(±0.8)
66.8
(±1.1)
64.1
(±0.9)
24.7
(±6.4)
51.7
(±9.0)
40.8
(±4.4)
64.8
(±4)
9.3
(±7.5)
0.8
(±1.5)
0 (0)

19.9
(±2.5)
39.6
(±3.6)

<0.01

<0.01

<0.01

<0.01

22.9
(±4.4)
39.9
(±6)

Median dose D50
(Gy)
Max dose D2% (Gy)
Min dose D98% (Gy)

CTV

Percentage covered
by 60.8 Gy (V95) %
Mean dose (Gy)
Max dose D2% (Gy)
Min dose D98% (Gy)

Rectum

V60Gy (%)
V40Gy (%)

Left
femur

Mean rectal dose
(Gy)
Max rectal dose D2%
(Gy)
V35Gy (%)
V45Gy (%)
V60Gy (%)
Mean FH dose (Gy)
Max FH dose D2%
(Gy)

P value
(comparing
means)

P value
(comparing
variances)

0.23

<0.01

0.08

<0.01

<0.01

<0.01

<0.01

<0.01

0.93

<0.01

<0.01

<0.01

0.84

<0.01

<0.01

0.22

<0.01

0.4

<0.01

0.81

<0.01

<0.01

0.62

<0.01

0.6
(±0.9)
0 (0)

0.32

<0.01

0.38

<0.01

20.5
(±2.6)
40.5
(±3.7)

<0.01

<0.01

0.4

<0.01

Fig. 1. Box and whisker plot demonstrating range of doses (max, min, mean and median) to PTV achieved in OTP and KBP plans. (Abbreviations: OTP: Original
treatment plan, KBP: Knowledge-based plan).

the radiation treatment plans could be improved. The KB plans, created
in less than 5 minutes, achieved significantly less variation in target
coverage as well as significantly lower doses to OARs. As expected,
improvements were seen when the comparison was made with all OTPs

due to the inclusion of plans created with older planning techniques.
However significant improvements were retained when the comparison
was made exclusively with IP-OTPs.
These finding were in keeping with a previous KBP prostate study
94
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Fig. 2. Box and whisker plot demonstrating range of doses according to TROG 08.03 protocol achieved to Rectal OAR in OTP, KBP, IP-OTP and IP-KBP plans.
(Abbreviations: OAR: Organ at Risk, OTP: Original treatment plan, KBP: Knowledge-based plan, IP-OTP: Inversely planned Original treatment plan, IP-KBP: Inversely
planned Knowledge-based plan).

Fig. 3. Box and whisker plot demonstrating range of doses according to TROG 08.03 protocol achieved to femoral head OAR in OTP, KBP, IP-OTP and IP-KBP plans.
(Abbreviations: OAR: Organ at Risk, OTP: Original treatment plan, KBP: Knowledge-based plan, IP-OTP: Inversely planned Original treatment plan, IP-KBP: Inversely
planned Knowledge-based plan).

rectal wall needs to be covered in the PPRT volumes, making dose
reduction more challenging. One exception was the rectal max dose
(D2%) which was significantly higher in the KB plans compared to both
the OTPs and IP-OTPs. Rectal max dose was not a violation in the TROG
08.03 trial and hence the model was not optimised with this constraint.
Subsequent KBP models could be further trained to reduce the rectal
max dose.
The trial required all major violations to be addressed and plans
resubmitted prior to commencement of treatment. The rate of resub
missions decreased as the study progressed, indicating both the presence
of an institutional learning curve and the importance of providing timely
feedback to clinicians. The most common dosimetric violation was
failure to meet rectal DVH constraints followed by PTV DVH violations
[26] but it was difficult for the QA team to know if violations were due to
poor planning or challenging anatomy (eg small rectum adjacent to
CTV). Consequently, the comprehensive QA process was labour

Table 3
Achievable dose constraints based on the 90th and 99th percentile in the KB
plans.
Contour
Rectum
Left femur

V60Gy
V40Gy
V35Gy
V45Gy

Dose constraints

Minor violation

Major violation

<25%
< 51%
< 15%
< 1.5%

25 – 32%
51 – 57%
15 – 20%
1.5–4%

>
>
>
>

32%
57%
20%
4%

which demonstrated homogeneity of target coverage and lower doses to
the OARs [19]. Another study on the implementation of KBP in prostate
cancer patients reported on a reduction in the average mean rectum dose
by 5.6 Gy [21]. Our study used patients receiving PPRT and the reduc
tion in mean rectal dose was 4.1 Gy for the full cohort and 1.2 Gy for the
IP cohort. The smaller reduction may be due to the fact that the anterior
95
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intensive and was at times a barrier to trial accrual [26]. Based on our
findings, one potential solution to the challenge of plan quality is using
KBP in order to provide patient specific plan QA rather than generic QA,
to ensure that only the highest quality plans are included in clinical
trials. When a plan is submitted for trial QA, a KBP model can be used to
predict DVHs for OARs. These patient specific OAR DVHs can be
compared with the DVH from the submitted plan. If the predicted DVH is
lower than the submitted DVH, the plan could be considered for
resubmission, with the OAR DVH predictions being provided as a guide
for input optimisation objectives during the replanning process. When
KB models are used to predict achievable OAR DVHs, studies have
shown strong correlation between predicted and achieved mean doses,
indicating that KB can accurately predict achievable mean doses[7]. Tol
et al reported that individualised QA could be performed in a few mi
nutes on head and neck plans and frequently improved doses to OARs,
even though the plans had met trial generic plan criteria [14]. A recent
publication investigated the role of KBP for real time treatment plan
review for stereotactic ablative body radiotherapy for kidney cancer.
They were able to provide real time feedback for 77% of their cases with
replan and improved OAR doses for 2 cases. All centres reported that the
QA check for their treatment plan was useful, despite timeline chal
lenges [20]. It must be acknowledged that not all planning systems are
the same and therefore the predicted DVHs may not be achievable on a
different planning systems, however they would provide a guide for plan
improvement. If a plan is submitted which meets trial criteria but KBP
indicates that it can be substantially improved, it would require clinical
judgement by the investigator or trial guidelines to determine whether a
resubmission is required.
Suggested dose constraints used in treatment plans and clinical trials
are based on QUANTEC data. In 2010, updated values were made
available from accumulation of 3D treatment planning data [29]. It has
been reported that the volume of rectum receiving ≥ 60 Gy is consis
tently associated with the risk of Grade ≥ 2 rectal toxicity or rectal
bleeding [30]. A systematic post-QUANTEC review of tolerance doses
for late toxicity after prostate radiotherapy was published by Olsson et
al, they reported on the importance of keeping doses at the lower
boundary of the tolerance curve to reduce toxicity [31]. With technol
ogy such as KBP, it has been demonstrated that lower doses to sur
rounding OARs can be achieved without compromising dose to targets,
and therefore OAR constraints should not necessarily be based on
QUANTEC but instead on the lowest doses achievable to ensure the best
quality plans. The rectal dose constraint on the TROG 08.03 trial was
V60Gy < 40%, yet in 90% of KBP cases, the V60Gy to the rectum
was<25% and in 99% of cases the dose was<32%. KBP is an effective
tool to guide us to achieve lower OAR doses in plans which would
otherwise have been considered to be acceptable.
There were several limitations to this study. Data for the full cohort
of patients treated on the original trial was not available. While only the
patients with the full dataset were used in our study, there is the po
tential for bias as the entire cohort was not included. All the plans
created with KBP were inversely planned while many of the OTPs were
created using 3DCRT. As the purpose of this study was to analyse the
potential of KBP as a clinical trial QA and planning tool, rather than to
directly compare the two planning techniques, the comparison was felt
to be acceptable. In addition, a secondary comparison was made be
tween only the IP-OTPs and their corresponding KB plans to allow for a
fairer comparison. DVH curves from the original plans were not avail
able, instead only the contours and dose points as recorded on the trial
evaluation forms. While the same dose points were used to make a direct
comparison, analysing the full DVH curves for both the OTP and KB
plans would have further contributed to the comparison of the two
treatment plans. The TROG 08.03 trial was established prior to 2008
when 3DCRT planning was used and dose constraints for the trial are
reflective of this. The trial evaluation form only recorded data as spec
ified on the protocol, specifically the Lt Femur, Rectum and PTV, as well
as doses to the CTV. There was no data recorded on the dose to the Right

femoral head or the bladder and therefore while we had this data from
the new KB Plans, a comparison was not possible. To more accurately
compare the OTP and the KB plans, information on dose to these addi
tional OARs would provide a more comprehensive plan comparison to
ensure dose was not being inappropriately delivered to these structures
while sparing the specified OARs.
In our study, KBP was able to create treatment plans in less than 5
minutes with improved OAR sparing despite the OTPs meeting trial plan
criteria and passing centralised QA. KBP is a powerful tool which should
be utilised in clinical trials for patient specific QA, to reduce dose to
surrounding OARs and to reduce the variations in plan quality which can
have an impact on the outcome of clinical trials.
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